Pharma Innovator Unlocks Multi-Disease Treatment Potential
Source: Jason Kolbert  (1/3/25)
Quince Therapeutics Inc. is "positioned for a transformative year" in 2025 with a solid cash position of US$47.8 million as of the third quarter of 2024. Find out why one analyst gives the stock a Buy rating. More >

Drug Innovator Launches Pivotal Cancer Trial Breakthrough
Source: Sean Lee  (1/3/25)
Corvus Pharmaceuticals, Inc. (CRVS:NASDAQ) has the potential to generate hundreds of millions of dollars over the next decade with its drug candidates, an H.C. Wainwright & Co. analyst wrote in a January 2 research note. More >

Miami Biopharma Sells Part of Business and Begins New Clinical Trial
Source: Dr. Yi Chen  (1/2/25)
Miami biopharmaceutical company Veru Inc. (VERU:NASDAQ) recently sold its FC2 Female Condom business for US$18 million, and has begun enrolling patients for its The Phase 2b QUALITY trial of enobosarm in combination with Wegovy (semaglutide) for sarcopenic obesity. Read on to see why one analyst gives this company a Buy rating. More >

Analyst Initiates Coverage of Co. With 'Once-in-a-Generation' Drug
Source: Ed Arce  (12/31/24)
NewAmsterdam Pharma Company N.V.'s (NAMS:NASDAQ) drug obicetrapib is a "once-in-a-generation" drug for cardiovascular disease, an analyst wrote in a research note while initiating coverage on the company. See what rating the stock got and its price per share target. More >

Analyst Sees Major Growth for Biopharma With Weight-Loss Drug
Source: Ed Arce  (12/31/24)
Recent successes of weight-loss drugs like Ozempic and Wegovy have led H.C. Wainwright & Co. Analyst Ed Arce to be "intrigued" by MetaVia Inc.'s (MTVA:NASDAQ) new drug candidate. More >

Parkinson's Treatment Advancements: Clinical Trials Begin for Potential New Therapy
Source: Streetwise Reports  (12/30/24)
Gain Therapeutics Inc. (GANX:NASDAQ) has announced the initiation of its Phase 1b clinical trial for GT-02287, a lead candidate targeting Parkinsons disease (PD), following regulatory approval in Australia. Read more about the trial aiming to redefine Parkinsons treatment and its potential global impact. More >

Maryland Biotech Gains Regulatory Approval
Source: Dr. Boobalan Pachaiyappan  (12/26/24)
Gain Therapeutics Inc. (GANX:NASDAQ) recently received Australian regulatory approval to begin GT-02287 evaluation in Parkinson's disease (PD) patients. More >

Pharma Co. Signs License Agreement With Boston Medical Center
Source: Edward White  (12/24/24)
60 Degrees Pharmaceuticals Inc. (SXTP:NASDAQ) announced a partnership to advance Arakoda (tafenoquine) for babesiosis with Boston-based Tufts Medical Center, according to an H.C. Wainwright & Co. research note. More >

FDA Expedites Review of Gene Therapy Co.'s Drug
Source: Streetwise Reports  (12/23/24)
Clinical stage genetic medicines company MeiraGTx Holdings Plc (MGTX:NASDAQ) says the FDA has granted regenerative medicine advance therapy (RMAT) designation to one of its treatments that could help thousands of patients. Read why one analyst thinks the stock is undersold. More >

Is This Centrally Positioned AI Healthcare Co. Set to Transform the Industry?
Source: Clive Maund  (12/20/24)
Technical Analyst Clive Maund explains why he thinks Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) offers potential upside to investors. More >

Medical Equipment Co. Shows Strong Profit Margin
Source: Dr. Douglas Loe  (12/20/24)
Despite this, the Buy-rated company remains undervalued by the markets due to ongoing business risk, noted a Leede Financial Inc. report. More >

Biopharma Using AI to Find Promising Cancer Drug Candidates
Source: Streetwise Reports  (12/19/24)
Biopharmaceutical company Rakovina Therapeutics Inc. (RKV:TSX.V) summarizes its achievements for 2024 and outlines its goals for the coming year. Find out how the company is using AI to accelerate drug development. More >

New Data Supports BLA Package
Source: Andrew Fein  (12/17/24)
Annexon Inc. (ANNX:NASDAQ) recently released real-world evidence data comparing it's ANX005 to standard treatments for Guillain-Barr Syndrome (GBS), according to an H.C. Wainwright & Co. research note. More >

New Quebec Law Affecting Healthcare Co.'s Bottom Line
Source: Douglas Lowe  (12/16/24)
Quebec-based staffing operator Premier Health of America Inc. (PHA:TSX.V) reported soft financial data for the fourth quarter of 2024 as the province's Bill 10 act limiting the use of per diem operations. Find out why this analyst thinks things will improve for the company. More >

Biotech's Parkinson's Drug Could Be Worth US$4B, Analyst Says
Source: Streetwise Reports  (12/10/24)
Clinical-stage biotechnology company Gain Therapeutics Inc.'s (GANX:NASDAQ) drug treating Parkinson's disease could be a "US$4 billion drug," according to one analyst who recently initiated coverage on the Maryland company. More >

California Biopharma Shows Promising Phase 1 Data
Source: Jason Kolbert  (12/9/24)
Artelo Biosciences Inc. (ARTL:NASDAQ) recently reported promising Phase 1 results from its CAReS trial evaluating ART27.13 for cancer-related anorexia, according to a D. Boral Capital research note. More >

FDA Decision on Drug for Bone Marrow Due Early 2025
Source: Dr. Douglas Loe  (12/6/24)
The manufacturer sheds light on the amount and remittance schedule of the cash payment it must remit to its partner if the drug gets approved, noted a Leede Financial Inc. report. More >

Drug Trial Shows Positive Interim Results for ALS Treatment
Source: Streetwise Reports  (12/6/24)
Biopharmaceutical company MediciNova Inc. (MNOV:NASDAQ) announced the release of a positive interim analysis of its treatment of Amyotrophic Lateral Sclerosis (ALS). Find out why one analyst says the drug has "potential" to treat the disease and maybe others. More >

AI Accelerates Breakthroughs in Cancer Drug Discovery
Source: Streetwise Reports  (12/3/24)
Rakovina Therapeutics Inc. (RKV:TSX.V) is advancing cancer drug discovery with its Deep Docking AI platform. Read more about their recent developments and future plans. More >

Intratubal Insemination Device Shown Effective, Safe
Source: Emily Bodnar  (12/3/24)
Pregnancy rates with this "only new innovation for infertility in decades" were "impressive" in a pivotal study in women with male factor infertility, noted an H.C. Wainwright & Co. report. More >

Approval Sought in Japan for New Drug to Lower Cholesterol
Source: Dr. Joseph Pantginis  (12/3/24)
The U.S. biopharma behind the drug is "pushing for accelerated adoption and expansion into additional territories," noted an H.C. Wainwright & Co. report. More >

Regenerative Medicine Co. Adds Saudi Arabia Diabetes Initiative
Source: Streetwise Reports  (12/3/24)
Leading regenerative medicine company Sernova Corp. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces agreement to explore fighting type I diabetes in Saudi Arabia. Read why one analyst believes the company's technology is "advanced." More >

Is This California Biopharma Co. In the Right Place at the Right Time?
Source: Dr. Jonathan Aschoff  (12/3/24)
Roth MKM analyst Dr. Jonathan Aschoff highlighted GT Biopharma Inc.'s (GTBP:NASDAQ) development of unique precision therapeutic agents using camelid-derived nanobodies. More >

Developer of Medical Instruments Attracts Research Coverage
Source: Douglas Loe  (12/2/24)
Both of this Buy-rated company's two business divisions are contributing to topline growth, noted a Leede Financial Inc. report. More >

Two Firms Aim To Create Functional Cure for Type 1 Diabetes
Source: Streetwise Reports  (11/22/24)
Each company is pursuing its own treatment approach to achieve insulin independence, consisting of islet cells (donor or stem cell derived), delivered into the portal vein or housed in a Cell Pouch bio-hybrid organ that is implanted in the body. Learn more about their respective programs. More >